172 related articles for article (PubMed ID: 12624789)
1. Expression of the CD34 antigen in pleomorphic xanthoastrocytomas.
Reifenberger G; Kaulich K; Wiestler OD; Blümcke I
Acta Neuropathol; 2003 Apr; 105(4):358-64. PubMed ID: 12624789
[TBL] [Abstract][Full Text] [Related]
2. BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression.
Koelsche C; Sahm F; Wöhrer A; Jeibmann A; Schittenhelm J; Kohlhof P; Preusser M; Romeike B; Dohmen-Scheufler H; Hartmann C; Mittelbronn M; Becker A; von Deimling A; Capper D
Brain Pathol; 2014 Apr; 24(3):221-9. PubMed ID: 24345274
[TBL] [Abstract][Full Text] [Related]
3. Genetic alterations commonly found in diffusely infiltrating cerebral gliomas are rare or absent in pleomorphic xanthoastrocytomas.
Kaulich K; Blaschke B; Nümann A; von Deimling A; Wiestler OD; Weber RG; Reifenberger G
J Neuropathol Exp Neurol; 2002 Dec; 61(12):1092-9. PubMed ID: 12484572
[TBL] [Abstract][Full Text] [Related]
4. Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas.
Weber RG; Hoischen A; Ehrler M; Zipper P; Kaulich K; Blaschke B; Becker AJ; Weber-Mangal S; Jauch A; Radlwimmer B; Schramm J; Wiestler OD; Lichter P; Reifenberger G
Oncogene; 2007 Feb; 26(7):1088-97. PubMed ID: 16909113
[TBL] [Abstract][Full Text] [Related]
5. Expression and release of CD14 in astrocytic brain tumors.
Deininger MH; Meyermann R; Schluesener HJ
Acta Neuropathol; 2003 Sep; 106(3):271-7. PubMed ID: 12835948
[TBL] [Abstract][Full Text] [Related]
6. Malignant progression in pleomorphic xanthoastrocytoma: personal experience and review of the literature.
Marton E; Feletti A; Orvieto E; Longatti P
J Neurol Sci; 2007 Jan; 252(2):144-53. PubMed ID: 17189643
[TBL] [Abstract][Full Text] [Related]
7. hTERT immunopositivity patterns in the normal brain and in astrocytic tumors.
Kotoula V; Cheva A; Barbanis S; Papadimitriou CS; Karkavelas G
Acta Neuropathol; 2006 Jun; 111(6):569-78. PubMed ID: 16614861
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of nucleostemin, a stem cell marker, and its variants in different types of brain tumors.
Malakootian M; Mowla SJ; Saberi H; Asadi MH; Atlasi Y; Shafaroudi AM
Mol Carcinog; 2010 Sep; 49(9):818-25. PubMed ID: 20572164
[TBL] [Abstract][Full Text] [Related]
9. Pleomorphic xanthoastrocytoma: DNA flow cytometry and outcome analysis of 12 patients.
Rostomily RC; Hoyt JW; Berger MS; Kros JM; Alvord EC; Wilkins P; Rabinovitch P
Cancer; 1997 Dec; 80(11):2141-50. PubMed ID: 9392337
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of CCAAT/enhancer binding protein beta correlates with prognosis in glioma patients.
Homma J; Yamanaka R; Yajima N; Tsuchiya N; Genkai N; Sano M; Tanaka R
Oncol Rep; 2006 Mar; 15(3):595-601. PubMed ID: 16465418
[TBL] [Abstract][Full Text] [Related]
11. Reduced expression of PDCD5 is associated with high-grade astrocytic gliomas.
Li H; Wang Q; Gao F; Zhu F; Wang X; Zhou C; Liu C; Chen Y; Ma C; Sun W; Zhang L
Oncol Rep; 2008 Sep; 20(3):573-9. PubMed ID: 18695908
[TBL] [Abstract][Full Text] [Related]
12. Pleomorphic xanthoastrocytoma: case report and analysis of the literature concerning the efficacy of resection and the significance of necrosis.
Pahapill PA; Ramsay DA; Del Maestro RF
Neurosurgery; 1996 Apr; 38(4):822-8; discussion 828-9. PubMed ID: 8692406
[TBL] [Abstract][Full Text] [Related]
13. Pleomorphic xanthoastrocytoma: a comparative pathological study between conventional and anaplastic types.
Hirose T; Ishizawa K; Sugiyama K; Kageji T; Ueki K; Kannuki S
Histopathology; 2008 Jan; 52(2):183-93. PubMed ID: 18184267
[TBL] [Abstract][Full Text] [Related]
14. Pleomorphic xanthoastrocytomas: immunohistochemistry, grading and clinico-pathologic correlations. An analysis of 34 cases from a single Institute.
Korshunov A; Golanov A
J Neurooncol; 2001 Mar; 52(1):63-72. PubMed ID: 11451204
[TBL] [Abstract][Full Text] [Related]
15. Intraventricular pleomorphic xanthoastrocytoma with anaplastic features.
Fu YJ; Miyahara H; Uzuka T; Natsumeda M; Okamoto K; Hirose T; Fujii Y; Takahashi H
Neuropathology; 2010 Aug; 30(4):443-8. PubMed ID: 20051018
[TBL] [Abstract][Full Text] [Related]
16. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
17. Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas.
Angileri FF; Aguennouz M; Conti A; La Torre D; Cardali S; Crupi R; Tomasello C; Germanò A; Vita G; Tomasello F
Cancer; 2008 May; 112(10):2258-66. PubMed ID: 18327814
[TBL] [Abstract][Full Text] [Related]
18. Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas.
Heimberger AB; McGary EC; Suki D; Ruiz M; Wang H; Fuller GN; Bar-Eli M
Clin Cancer Res; 2005 Jan; 11(1):267-72. PubMed ID: 15671555
[TBL] [Abstract][Full Text] [Related]
19. Identification of MG-160, a FGF binding medial Golgi sialoglycoprotein, in brain tumors: an index of malignancy in astrocytomas.
Yamaguchi F; Morrison RS; Gonatas NK; Takahashi H; Sugisaki Y; Teramoto A
Int J Oncol; 2003 May; 22(5):1045-9. PubMed ID: 12684670
[TBL] [Abstract][Full Text] [Related]
20. Tenascin-C expression relates to clinicopathological features in pilocytic and diffuse astrocytomas.
Maris C; Rorive S; Sandras F; D'Haene N; Sadeghi N; Bièche I; Vidaud M; Decaestecker C; Salmon I
Neuropathol Appl Neurobiol; 2008 Jun; 34(3):316-29. PubMed ID: 17983425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
